JP2012010714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012010714A5 JP2012010714A5 JP2011227423A JP2011227423A JP2012010714A5 JP 2012010714 A5 JP2012010714 A5 JP 2012010714A5 JP 2011227423 A JP2011227423 A JP 2011227423A JP 2011227423 A JP2011227423 A JP 2011227423A JP 2012010714 A5 JP2012010714 A5 JP 2012010714A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (20)
- ボツリヌス神経毒素(BoNT)に結合する単離された抗体であって、該抗体は、以下:
a)配列番号89のアミノ酸配列を含むV L CDR1;
b)配列番号91のアミノ酸配列を含むV L CDR2;
c)配列番号119のアミノ酸配列を含むV L CDR3;ならびに、
d)以下:
i)配列番号33のアミノ酸配列を含むV H CDR1;
ii)配列番号35のアミノ酸配列を含むV H CDR2;および
iii)配列番号63のアミノ酸配列を含むV H CDR3
を含むV H CDR、または、
以下:
i)配列番号25のアミノ酸配列を含むV H CDR1;
ii)配列番号27のアミノ酸配列を含むV H CDR2;および
iii)配列番号57のアミノ酸配列を含むV H CDR3
を含むV H CDR
を含む、単離された抗体。 - 前記抗体が、以下:
i)配列番号33のアミノ酸配列を含むV H CDR1;
ii)配列番号35のアミノ酸配列を含むV H CDR2;および
iii)配列番号63のアミノ酸配列を含むV H CDR3
を含む、請求項1に記載の単離された抗体。 - 前記抗体が、以下:
a)配列番号9のアミノ酸配列を含む重鎖;および
b)配列番号22のアミノ酸配列を含む軽鎖
を含む、請求項2に記載の単離された抗体。 - 前記抗体が、以下:
a)配列番号23のアミノ酸配列を含む重鎖;および
b)配列番号22のアミノ酸配列を含む軽鎖
を含む、請求項2に記載の単離された抗体。 - 前記抗体が、以下:
i)配列番号25のアミノ酸配列を含むV H CDR1;
ii)配列番号27のアミノ酸配列を含むV H CDR2;および
iii)配列番号57のアミノ酸配列を含むV H CDR3
を含む、請求項1に記載の単離された抗体。 - 前記抗体が、以下:
a)配列番号7のアミノ酸配列を含む重鎖;および
b)配列番号22のアミノ酸配列を含む軽鎖
を含む、請求項5に記載の単離された抗体。 - 前記抗体が、以下:
a)配列番号8のアミノ酸配列を含む重鎖;および
b)配列番号22のアミノ酸配列を含む軽鎖
を含む、請求項5に記載の単離された抗体。 - 前記抗体が、単鎖Fv(scFv)抗体、IgG抗体、Fab抗体、(Fab’) 2 抗体または(scFv’) 2 抗体である、請求項1〜7のいずれか1項に記載の単離された抗体。
- ボツリヌス神経毒素(BoNT)を中和するための組成物であって、該組成物は、1つのBoNT血清型につき少なくとも2種の異なる抗体を含み、該2種の異なる抗体のうちの第1の抗体は、請求項1〜8のいずれか1項に記載の抗体である、組成物。
- 前記2種の異なる抗体が、血清型BoNT/A1およびBoNT/A2のうちの少なくとも1つに同時に結合する、請求項9に記載の組成物。
- 前記2種の異なる抗体のうちの第2の抗体は、以下:
a)i)配列番号11のアミノ酸配列を含む重鎖と、
ii)配列番号10もしくは配列番号354のアミノ酸配列を含む軽鎖と
を含む抗体;
b)i)配列番号9もしくは配列番号23のアミノ酸配列を含む重鎖と、
ii)配列番号22のアミノ酸配列を含む軽鎖と
を含む抗体;
c)i)配列番号12のアミノ酸配列を含む重鎖と、
ii)配列番号358、配列番号13、配列番号14もしくは配列番号15のアミノ酸配列を含む軽鎖と
を含む抗体;ならびに
d)i)配列番号16のアミノ酸配列を含む重鎖と、
ii)配列番号362のアミノ酸配列を含む軽鎖と
を含む抗体;
からなる群より選択される、請求項9に記載の組成物。 - 前記2種の異なる抗体のうちの第2の抗体は、以下:
a)i)配列番号11のアミノ酸配列を含む重鎖と、
ii)配列番号10もしくは配列番号354のアミノ酸配列を含む軽鎖と
を含む抗体;
b)i)配列番号9もしくは配列番号23のアミノ酸配列を含む重鎖と、
ii)配列番号22のアミノ酸配列を含む軽鎖と
を含む抗体;ならびに
c)i)配列番号16のアミノ酸配列を含む重鎖と、
ii)配列番号362のアミノ酸配列を含む軽鎖と
を含む抗体;
からなる群より選択される、請求項9に記載の組成物。 - 前記抗体が、薬学的に受容可能な賦形剤中に存在する、請求項9に記載の組成物。
- 前記組成物が単位投薬処方物である、請求項9に記載の組成物。
- 哺乳動物におけるボツリヌス神経毒素(BoNT)を中和するための組合せ物であって、該組合せ物は、1つのBoNT血清型につき2種の異なる抗体を含み、該2種の異なる抗体のうちの第1の抗体は、請求項1〜8のいずれか1項に記載の抗体である、組合せ物。
- 前記2種の異なる抗体のうちの第2の抗体が、以下:
a)i)配列番号11のアミノ酸配列を含む重鎖と、
ii)配列番号10もしくは配列番号354のアミノ酸配列を含む軽鎖と
を含む抗体;
b)i)配列番号9もしくは配列番号23のアミノ酸配列を含む重鎖と、
ii)配列番号22のアミノ酸配列を含む軽鎖と
を含む抗体;
c)i)配列番号12のアミノ酸配列を含む重鎖と、
ii)配列番号358、配列番号13、配列番号14もしくは配列番号15のアミノ酸配列を含む軽鎖と
を含む抗体;または
d)i)配列番号16のアミノ酸配列を含む重鎖と、
ii)配列番号362のアミノ酸配列を含む軽鎖と
を含む抗体;
からなる群より選択される、請求項15に記載の組合せ物。 - 前記2種の異なる抗体のうちの第2の抗体が、以下:
a)i)配列番号11のアミノ酸配列を含む重鎖と、
ii)配列番号10もしくは配列番号354のアミノ酸配列を含む軽鎖と
を含む抗体;
b)i)配列番号9もしくは配列番号23のアミノ酸配列を含む重鎖と、
ii)配列番号22のアミノ酸配列を含む軽鎖と
を含む抗体;または
c)i)配列番号16のアミノ酸配列を含む重鎖と、
ii)配列番号362のアミノ酸配列を含む軽鎖と
を含む抗体;
からなる群より選択される、請求項15に記載の組合せ物。 - ボツリヌス神経毒素を中和するためのキットであって、該キットは、以下:
請求項9〜14のいずれか1項に記載の組成物;および
ボツリヌス神経毒素に結合させるための該組成物の使用を教示する指示資料
を備える、キット。 - 前記組成物が使い捨て可能な注射器中に収容される、請求項18に記載のキット。
- 請求項1〜8のいずれか1項に記載の抗体をコードする核酸。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64825605P | 2005-01-27 | 2005-01-27 | |
US60/648,256 | 2005-01-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008500705A Division JP2008528060A (ja) | 2005-01-27 | 2006-01-26 | ボツリヌス神経毒素を中和する治療的モノクローナル抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012010714A JP2012010714A (ja) | 2012-01-19 |
JP2012010714A5 true JP2012010714A5 (ja) | 2012-12-06 |
Family
ID=38371918
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008500705A Pending JP2008528060A (ja) | 2005-01-27 | 2006-01-26 | ボツリヌス神経毒素を中和する治療的モノクローナル抗体 |
JP2011227423A Pending JP2012010714A (ja) | 2005-01-27 | 2011-10-14 | ボツリヌス神経毒素を中和する治療的モノクローナル抗体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008500705A Pending JP2008528060A (ja) | 2005-01-27 | 2006-01-26 | ボツリヌス神経毒素を中和する治療的モノクローナル抗体 |
Country Status (7)
Country | Link |
---|---|
US (3) | US7700738B2 (ja) |
EP (2) | EP2153848A3 (ja) |
JP (2) | JP2008528060A (ja) |
CN (1) | CN101146554B (ja) |
AU (1) | AU2006332045A1 (ja) |
CA (1) | CA2594297A1 (ja) |
WO (1) | WO2007094754A2 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US7700738B2 (en) | 2005-01-27 | 2010-04-20 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
ES2398076T3 (es) * | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
EP2134749B1 (en) | 2007-03-22 | 2013-11-06 | The Regents of the University of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US7732579B2 (en) * | 2007-06-13 | 2010-06-08 | The United States Of America As Represented By The Secretary Of Agriculture | High-affinity monoclonal antibodies for botulinum toxin type A |
US8540987B2 (en) * | 2008-01-29 | 2013-09-24 | Institute For Antibodies Co., Ltd. | Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody |
CA2732003A1 (en) | 2008-07-31 | 2010-02-04 | James D. Marks | Antibodies that neutralize botulinum neurotoxins |
CN102980999A (zh) * | 2008-11-27 | 2013-03-20 | 上海交通大学 | 检测莱克多巴胺的化学发光免疫检测试剂盒 |
WO2011028962A1 (en) * | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Antibody coformulations |
US8821879B2 (en) | 2009-09-04 | 2014-09-02 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
US20120269822A1 (en) | 2009-10-20 | 2012-10-25 | Marks James D | Anti-Botulinum Neurotoxin a Single Domain Antibody Antibodies |
MY171234A (en) | 2010-02-24 | 2019-10-04 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
NZ603226A (en) | 2010-04-30 | 2015-02-27 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
FR2962439A1 (fr) * | 2010-07-12 | 2012-01-13 | Lfb Biotechnologies | Anticorps monoclonaux diriges contre la toxine tetanique |
US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
US9243057B2 (en) | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
US9474454B2 (en) * | 2010-10-20 | 2016-10-25 | Advanced Mri Technologies Llc | MRI using faster multiplexed echo planar imaging (EPI) pulse sequences |
IL303208A (en) | 2011-04-01 | 2023-07-01 | Immunogen Inc | Methods for increasing the effectiveness of FOLR1 cancer therapy |
NZ726258A (en) | 2012-08-31 | 2019-07-26 | Immunogen Inc | Antibodies and uses thereof to detect folate receptor 1 |
EP2931749B1 (fr) | 2012-12-17 | 2019-04-24 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
KR20230145514A (ko) | 2013-08-30 | 2023-10-17 | 이뮤노젠 아이엔씨 | 엽산 수용체 1의 검출을 위한 항체 및 분석 |
RU2749865C2 (ru) | 2015-09-17 | 2021-06-17 | Иммьюноджен, Инк. | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты |
DK3481852T3 (da) * | 2016-07-08 | 2023-02-27 | Childrens Medical Center | Hidtil ukendt botulinum-neurotoksin og dets derivater |
CN110317268B (zh) * | 2019-07-01 | 2021-06-29 | 中国人民解放军军事科学院军事医学研究院 | 一种中和a型肉毒毒素的鼠源单抗及其应用 |
CN114621348B (zh) * | 2022-01-24 | 2023-09-22 | 深圳市乐土生物医药有限公司 | 一种多肽及其抗磷脂酰肌醇蛋白聚糖3抗体 |
CN116925213B (zh) * | 2023-09-12 | 2024-03-15 | 中国人民解放军军事科学院军事医学研究院 | 一种中和a型肉毒毒素的纳米抗体 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4254082A (en) | 1978-06-12 | 1981-03-03 | Miles Laboratories, Inc. | Specific binding-adsorbent assay test means |
US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
JPS58215453A (ja) | 1982-06-09 | 1983-12-14 | Toray Silicone Co Ltd | 室温硬化後塗装可能なオルガノポリシロキサン組成物 |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4689299A (en) | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5169939A (en) | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
US5306730A (en) | 1986-02-03 | 1994-04-26 | Kabushiki Kaisha Yakult Honsha | Botulinum toxin neutralizer |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
IL84285A (en) | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5001065A (en) | 1987-05-27 | 1991-03-19 | Cetus Corporation | Human cell line and triomas, antibodies, and transformants derived therefrom |
JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5231026A (en) | 1987-12-31 | 1993-07-27 | Tanox Biosystems, Inc. | DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE |
US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
US5292867A (en) | 1988-11-16 | 1994-03-08 | Tanox Biosystems, Inc. | Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin |
IL94872A (en) | 1989-06-30 | 1995-03-30 | Oncogen | Monoclonal or chimeric antibodies that react with human carcinoma, recombinant proteins that contain their anti-binding site, pharmaceutical preparations and kits that contain the |
US5075431A (en) | 1989-07-26 | 1991-12-24 | City Of Hope | Chimeric anti-CEA antibody |
US5081235A (en) | 1989-07-26 | 1992-01-14 | City Of Hope | Chimeric anti-cea antibody |
US5599539A (en) | 1989-10-31 | 1997-02-04 | Ophidian Pharmaceuticals, Inc. | Therapy for clostridial botulinum toxin |
US5719267A (en) | 1989-10-31 | 1998-02-17 | Ophidian Pharmaceuticals Inc. | Clostridial toxin disease therapy |
US5919665A (en) | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5472693A (en) | 1993-02-16 | 1995-12-05 | The Dow Chemical Company | Family of anti-carcinoembryonic antigen chimeric antibodies |
JP3382295B2 (ja) * | 1993-04-22 | 2003-03-04 | キヤノン株式会社 | 像振れ補正装置 |
US5506132A (en) | 1993-07-28 | 1996-04-09 | Sandoz Pharmaceuticals Corporation | Human antibodies against varicella-zoster virus |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
US7214787B1 (en) | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
EP1181937A3 (en) | 1994-08-09 | 2004-02-04 | Cytrx Corporation | Novel vaccine adjuvant and vaccine |
EP0811163A1 (en) | 1995-02-13 | 1997-12-10 | Microbiological Research Authority | Diagnosis of toxicoinfectious clostridiosis |
US5691447A (en) | 1995-03-24 | 1997-11-25 | Tanox Biosystems, Inc. | GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies |
US5731161A (en) | 1995-04-24 | 1998-03-24 | Allergan, Inc. | Botulinum toxin antibody detection assay |
US5807741A (en) | 1995-07-20 | 1998-09-15 | Brown; Douglas Richard | Neutralizing monoclonal antibody against botulinum neurotoxin serotype F |
US5932449A (en) | 1996-02-01 | 1999-08-03 | The United States Of America As Represented By The Secretary Of The Army | Detection of botulinum toxin |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
US6794128B2 (en) | 1998-04-24 | 2004-09-21 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
DE19828466A1 (de) | 1998-06-26 | 1999-12-30 | Roche Diagnostics Gmbh | Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind |
WO2000002524A2 (en) | 1998-07-10 | 2000-01-20 | U.S. Army Medical Research Institute Of Infectious Diseases | Botulinum neurotoxin vaccine |
US20020155114A1 (en) | 1998-08-31 | 2002-10-24 | James D. Marks | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US6667158B1 (en) | 1998-12-17 | 2003-12-23 | The United States Of America As Represented By The Secretary Of The Army | Antibodies against type a botulinum neurotoxin |
WO2000069895A2 (en) | 1999-05-14 | 2000-11-23 | U.S. Army Medical Research And Material Command | Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins |
US6573244B1 (en) | 1999-05-17 | 2003-06-03 | The United States Of America As Represented By The Secretary Of The Army | Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins |
US20040220100A1 (en) | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
DE60131468D1 (de) | 2000-09-25 | 2007-12-27 | U S Medical Res Inst Of Infect | Hoch-durchsatz assays für proteolytische aktivitäten von clostridium neurotoxinen |
ATE541047T1 (de) | 2002-08-01 | 2012-01-15 | Univ California | Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen |
WO2005030119A2 (en) | 2003-04-11 | 2005-04-07 | Allergan, Inc. | Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
US7157562B1 (en) | 2003-04-14 | 2007-01-02 | The United States Of America As Represented By The Secretary Of The Army | Bioprocess for the production of recombinant anti-botulinum toxin antibody |
GB0312642D0 (en) | 2003-06-03 | 2003-07-09 | Secr Defence | Pharmaceutical composition |
US7700738B2 (en) | 2005-01-27 | 2010-04-20 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
TWI552751B (zh) | 2011-06-20 | 2016-10-11 | H 朗德貝克公司 | 投予4-((1r,3s)-6-氯-3-苯基-二氫茚-1-基)-1,2,2-三甲基-哌及其鹽用於治療精神分裂症的方法 |
-
2006
- 2006-01-26 US US11/342,271 patent/US7700738B2/en active Active
- 2006-01-26 EP EP09011256A patent/EP2153848A3/en not_active Withdrawn
- 2006-01-26 AU AU2006332045A patent/AU2006332045A1/en not_active Abandoned
- 2006-01-26 EP EP06849678A patent/EP1850866A4/en not_active Withdrawn
- 2006-01-26 JP JP2008500705A patent/JP2008528060A/ja active Pending
- 2006-01-26 CN CN2006800097157A patent/CN101146554B/zh active Active
- 2006-01-26 CA CA002594297A patent/CA2594297A1/en not_active Abandoned
- 2006-01-26 WO PCT/US2006/003070 patent/WO2007094754A2/en active Application Filing
-
2009
- 2009-12-23 US US12/646,705 patent/US7999079B2/en active Active
-
2011
- 2011-07-01 US US13/175,628 patent/US20120177663A1/en not_active Abandoned
- 2011-10-14 JP JP2011227423A patent/JP2012010714A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012010714A5 (ja) | ||
HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
JP2009225799A5 (ja) | ||
JP2016507470A5 (ja) | ||
JP2020023523A5 (ja) | ||
JP2015535828A5 (ja) | ||
JP2015503909A5 (ja) | ||
RU2017123549A (ru) | Антитела, нацеленные на антиген созревания в-клеток, и способы их применения | |
JP2014205674A5 (ja) | ||
JP2018536393A5 (ja) | ||
JP2017052784A5 (ja) | ||
JP2015514110A5 (ja) | ||
RU2016100892A (ru) | Антитела против tweakr и их применение | |
JP2011517447A5 (ja) | ||
JP2018500014A5 (ja) | ||
JP2017505125A5 (ja) | ||
JP2017535257A5 (ja) | ||
JP2018535650A5 (ja) | ||
RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
JP2016516400A5 (ja) | ||
JP2017507652A5 (ja) | ||
JP2013506428A5 (ja) | ||
JP2018502561A5 (ja) | ||
RU2020129387A (ru) | Антитела к pd-1 собак | |
JP2014511179A5 (ja) |